Trinity Biotech PLC $ 0.8 -0.04 (-4.83%)
Volume:
45,900
Avg Vol (1m):
118,944
Market Cap $:
16.72 Mil
Enterprise Value $:
73.50 Mil
P/E (TTM):
0.00
P/B:
0.52
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $0.8 | ||
Manual of Stocks™ Web
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.31 | ||
| Equity-to-Asset | 0.23 | ||
| Debt-to-Equity | 2.1 | ||
| Debt-to-EBITDA | -4.26 | ||
| Interest Coverage | 1.07 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 1.04 | ||
| WACC vs ROIC | |||
Profitability | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 6.19 | ||
| Net Margin % | -31.56 | ||
| ROE % | -63.06 | ||
| ROA % | -17.33 | ||
| ROC (Joel Greenblatt) % | -36.91 | ||
| 3-Year Revenue Growth Rate | 0.8 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 0.52 | ||
| PS Ratio | 0.22 | ||
| Price-to-Operating-Cash-Flow | 2.07 | ||
| EV-to-EBIT | -3.83 | ||
| EV-to-EBITDA | -3.83 | ||
| EV-to-Revenue | 0.78 | ||
| Current Ratio | 3.13 | ||
| Quick Ratio | 1.97 | ||
| Days Inventory | 208.23 | ||
| Days Sales Outstanding | 96.71 | ||
| Days Payable | 134.7 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Dividend Growth Rate | -100 | ||
| 3-Year Average Share Buyback Ratio | 4.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Median-PS-Value | 0.09 | ||
| Earnings Yield (Greenblatt) % | -26.11 | ||
| Forward Rate of Return (Yacktman) % | -65.95 |